China's Food and Drug Administration convened a meeting of traditional-Chinese-medicine officials from 17 cities to discuss regulating the medical ingredient market, after recent inspections found counterfeit medicines and illegal operations. "Firm determination should be used to rectify the market," said Wu Zhen, CFDA deputy director, including punishing offenders, closing affected medical ingredient centers and holding officials accountable.

Related Summaries